Last updated: March 13, 2026
What is NDC 50383-0311?
NDC 50383-0311 corresponds to Tucatinib (trade name: Tukysa), a tyrosine kinase inhibitor approved by the FDA in April 2020 for the treatment of HER2-positive metastatic breast cancer.
Market Size and Demand Dynamics
1. Market Overview
Tucatinib’s approvals target a niche within oncology: HER2-positive metastatic breast cancer, particularly for patients who have received prior therapies. The drug competes with other HER2-targeted agents such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine.
2. Patient Population
- Estimated US prevalence of HER2-positive metastatic breast cancer: approximately 35,000–50,000 patients annually.
- Patients eligible for tucatinib (post-chemotherapy and trastuzumab-based regimens): around 10,000–15,000.
- Global market potential considers emerging markets with expanding access and diagnosis rates.
3. Market Penetration
- Initial launch in 2020 faced slow uptake, driven primarily by awareness and reimbursement hurdles.
- Adoption has increased following positive phase 3 HER2CLIMB trial results demonstrating improved progression-free survival (PFS) and overall survival (OS).
- Forecasted rapid growth as standards of care incorporate tucatinib more widely.
4. Competitive Landscape
| Drug |
Approved Indications |
Market share (2022) |
Annual Sales (2022) |
Notes |
| Trastuzumab (Herceptin) |
Multiple HER2+ breast cancers |
60% |
$6.5 billion |
Established position, high penetration |
| Pertuzumab (Perjeta) |
HER2+ early and metastatic breast cancer |
20% |
$2.1 billion |
Standard of care in combination |
| Ado-trastuzumab emtansine |
HER2+ metastatic breast cancer |
10% |
$1.8 billion |
Used after trastuzumab and pertuzumab |
Tucatinib's share is expected to grow from near zero in 2020 to approximately 10–15% in 2025.
Price Projections
1. List Price Vs. Actual Reimbursements
- The FDA-approved list price for tucatinib in the US was approximately $11,185 per month in 2022.
- Actual reimbursement prices vary significantly based on payer negotiations, discounts, and patient assistance programs.
2. Cost Trajectory
- Patent exclusivity granted until at least 2030, preventing generic competition.
- Price reductions are unlikely before patent expiry unless negotiated discounts or biosimilar entrants occur.
3. Market-Driven Price Adjustments
- As market penetration deepens and competition increases, prices may trend downward, with potential reductions of 10–20% by 2026 in real-world settings.
- Volume growth compensates for lower per-unit pricing, supporting steady revenue streams.
4. Emerging Markets and Price Sensitivity
- In Europe and Asia, prices are generally 30–50% lower than US levels.
- Price controls and healthcare budgets influence availability and pricing strategies in these regions.
Revenue Projections (2023–2028)
| Year |
Estimated US Sales |
Global Sales |
Market Share Assumption |
Key Drivers |
| 2023 |
$300 million |
$400 million |
4–6% of total HER2+ breast cancer therapy |
Early adoption, increased awareness |
| 2024 |
$600 million |
$800 million |
8–10% |
Significant clinical guideline inclusion, payer coverage |
| 2025 |
$1 billion |
$1.3 billion |
12–15% |
Expanded access, geographic expansion |
| 2026 |
$1.2 billion |
$1.6 billion |
15–20% |
Market saturation, price reductions |
| 2027 |
$1.3 billion |
$1.7 billion |
17–20% |
Steady demand, competitive dynamics |
| 2028 |
$1.4 billion |
$1.8 billion |
18–20% |
Mature market, stable pricing |
Regulatory and Reimbursement Factors
- Patients in Medicare and commercial insurance plans cover higher co-pays.
- US Medicare Part B and Part D policies influence pricing and reimbursement models.
- Payer negotiations are key in optimizing market access, especially in biosimilar and generic landscapes.
Key Competitors and Competitive Strategies
- Differentiation through efficacy in brain metastases (a common complication in HER2+ breast cancer).
- Strategic partnerships with payers and providers to ensure reimbursement.
- Focused clinical trials to expand indications.
Conclusions
- Tucatinib is positioned as a niche but growing therapy within HER2-positive breast cancer.
- Market penetration depends on clinical adoption, reimbursement, and competitive positioning.
- Price projections anticipate steady increases in revenue driven by expanding indications and market access, with pricing pressures emerging after patent expiration.
Key Takeaways
- Tucatinib's US launch price was approximately $11,185/month, with real-world prices potentially lower due to discounts.
- US sales could reach $1–1.4 billion annually by 2028, contingent on market uptake.
- Global sales are expected to mirror US growth but at lower prices.
- Competition from established HER2 therapies will influence sales velocity and pricing strategies.
- Price reductions may accelerate post-2030 with biosimilar entry.
FAQs
Q1: How does tucatinib compare in efficacy to other HER2-targeted therapies?
Tucatinib demonstrated improved progression-free survival and overall response rates in the HER2CLIMB trial, especially showing activity against brain metastases, a common challenge in HER2-positive breast cancer.
Q2: What factors influence tucatinib’s pricing strategy?
Market exclusivity, clinical value, payer negotiations, regional pricing policies, and competition impact pricing decisions.
Q3: How susceptible is tucatinib to biosimilar competition?
If biosimilars or generics enter post-patent expiry around 2030, prices could decrease by 30–50% depending on market dynamics.
Q4: What is the primary driver for tucatinib's future sales growth?
Expanded clinical indications, broader geographic access, and increased clinician familiarity will drive growth.
Q5: How do reimbursement policies impact tucatinib’s market penetration?
Reimbursement is critical; payer coverage determines patient access. Positive policy decisions and inclusion in treatment guidelines support faster adoption.
[1] U.S. Food and Drug Administration. (2020). Tucatinib (Tukysa) approval.
[2] EvaluatePharma. (2022). HER2-positive breast cancer drugs sales data.
[3] IQVIA. (2022). Global Oncology Market Reports.
